Publications by authors named "Michiya Ota"

Background/aim: Although multiple treatments are available for metastatic castration-resistant prostate cancer, data to determine the optimal treatment sequence are limited. This study aimed to investigate the current status of drug therapy for castration-resistant prostate cancer and clarify the sequential treatment in actual clinical practice.

Patients And Methods: This retrospective study included 425 patients diagnosed with castration-resistant prostate cancer at Showa University Hospital and affiliated hospitals between January 2014 and December 2021, who were treated with any of the following four drugs: novel androgen receptor signal inhibitors (abiraterone acetate and enzalutamide) and anticancer drugs (docetaxel and cabazitaxel).

View Article and Find Full Text PDF
Article Synopsis
  • Enzalutamide is an oral medication that helps prolong survival in men with castration-resistant prostate cancer (CRPC) and was evaluated for its effectiveness and safety in a study of 73 patients.
  • The study found that patients without prior docetaxel treatment had a better response to enzalutamide, with 61.4% achieving a significant reduction in PSA levels, compared to only 24.1% in those who had received docetaxel.
  • Common side effects included fatigue, anorexia, and nausea, and some patients experienced a PSA flare, which can occur in those who respond to treatment.
View Article and Find Full Text PDF

Organic solvent extracts from fresh twig bark of Japanese pear cultivars (Pyrus serotina) Shinko and Nijisseiki, and European pear cultivar (P. communis) Le Lectier were obtained by maceration with n-hexane and EtOAc, and analyzed in GC-EIMS experiments. In these two Japanese cultivars, the lupeol, betulin, epifriedelinol, friedelin and arbutin contents of Nijisseiki were higher than those of Shinko.

View Article and Find Full Text PDF